-+ 0.00%
-+ 0.00%
-+ 0.00%

Edwards Lifesciences Q2 FY26 EPS drops to $0.42; net sales rise 13.6% to $1.74 billion

PUBT·07/23/2026 20:37:11
Listen to the news
Edwards Lifesciences Q2 FY26 EPS drops to $0.42; net sales rise 13.6% to $1.74 billion
  • Edwards Lifesciences Q2 net sales rose 13.6% to USD 1.74 billion; GAAP diluted EPS fell to USD 0.42.
  • GAAP net income attributable to shareholders dropped to USD 241.9 million; effective tax rate widened to 53.6%.
  • TMTT net sales more than doubled to USD 195.9 million; TAVR net sales climbed 11.3% to USD 1.26 billion.
  • 2026 outlook raised for total company net sales growth to 10%-11%; adjusted EPS guidance held at USD 2.95-3.05.
  • CEO Bernard Zovighian cited stronger-than-expected sales growth, supported by contributions across regions and therapies including TAVR, mitral, tricuspid, surgical.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607231615BIZWIRE_USPR_____20260723_BW783980) on July 23, 2026, and is solely responsible for the information contained therein.